Cholangiocarcinoma (CCA) originates from the biliary tract. CCA is associated with a high mortality rate and a concerning increase in incidence. Tumour heterogeneity complicates treatment therefore stratifying patients based on their molecular signature and biomarker-guided therapy may be an effective solution. Here we show that there are five molecular subtypes in CCA based on the gene expression profile of selected RTKs (RTK25). We also identified potential therapeutics that can target each of these molecular profile for drug repurposing in CCA using in silico analysis. Moreover, the results showed that certain RTKs are expressed together suggesting that that there might be cross-talk of RTKs in CCA. This encourages future investigations to examine the efficacy as well as mechanism of dual-RTK inhibition as a therapeutic strategy in CCA. The novel RTK25 molecular profiling strategy provides new insights into molecular characterization of CCA patients.
Balasubramanian B, Venkatraman S, Janvilisri T, Suthiphongchai T, Jitkaew S, Sripa J, Tohtong R. RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals. 2021 Sep;14(9):898. PMID: 34577598
|Assoc. Prof. Rutaiwan Tohtong